Business, energy, technology, markets and global industry news from Business News Today

LATITUDE Atlas

PharmaDeviceNews LATITUDE Atlas
Psoriasis treatment innovation moves closer to market as the US Food and Drug Administration grants Priority Review to Takeda’s zasocitinib following positive Phase 3 trial results, including head-to-head superiority over deucravacitinib in plaque psoriasis. Representative image.
Pharma & Biotech

Zasocitinib beat an approved TYK2 rival head to head. Can Takeda turn that into a new oral psoriasis benchmark?

FDA grants Priority Review to Takeda’s zasocitinib after Phase 3 psoriasis studies, including head-to-head superiority versus deucravacitinib.

Read More